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Background. Two thirds of new TB cases in sub-Saharan Africa are HIV co-
infected. HIV-TB co-infection increases the incidence of extra-pulmonary, 
sputum smear-negative and sputum-scarce TB. In these vulnerable patient-
groups with high mortality rates, sputum-based diagnostic tools are unhelpful. 
Urine-based diagnostics offer an attractive, easily available alternative for rapid 
diagnosis. We evaluated the point-of-care urine LAM strip test (Determine TB 
LAM Ag test, Alere) and urine-based Xpert MTB/RIF for TB diagnosis in two 
patient cohorts with high HIV prevalence. 
 
Methods: A spot urine sample was collected from two cohorts of persons with 
suspected TB. The first cohort consisted of ambulatory primary care clinic 
patients suspected of having TB (group 1) whilst the second comprised 
hospitalised patients with suspected HIV co-infection (group 2). The urine LAM 
ELISA, LAM strip test and Xpert MTB/RIF were performed according to the 
manufacturer’s instructions. In addition, the effects of using an alternative ‘rule-
in’ cut-point for the urine LAM strip test and a pelleted (2-10ml) urine sample 
for Xpert MTB/RIF testing on diagnostic accuracy and inter-reader reliability 
was assessed. The diagnostic reference standard was M. tuberculosis culture 
positivity.  
 
Results: Amongst group 1 out-patients, 28% (80/287) were HIV-infected and 
14% (40/287) were M. tuberculosis culture positive. In group 1 HIV-infected 
patients using the grade-1 cut-point, the sensitivity (95%CI) and specificity 
(95%CI) of the LAM strip test was 24% (11-45) and 84% (73-92), respectively. 












specificity (84% vs 100%, p=0.02) and inter-rater agreement (84% vs. 100%, 
p=0.001) but sensitivity decreased to 5% (1-23).  
Amongst group 2 hospitalised-patients, 83% (280/335) were HIV-infected and 
42% (116/280) were M. tuberculosis culture positive. In HIV-infected patients the 
sensitivity (95%CI) of both urine LAM strip test (grade-2 cut-point) and urine-
based Xpert-MTB/RIF was 48% (39-57). Combined sensitivity of urine LAM and 
Xpert MTB/RIF was better than each test alone [combined: 64% (55-73) vs. LAM 
strip test: 48% (39-57), p=0.014 vs. MTB/RIF: 48% (39-57), p=0.014]. In sputum-
scarce, culture positive patients, urine-based Xpert MTB/RIF had a sensitivity of 
40% (8/20). For Xpert MTB/RIF, the use of 2-10ml of pelleted urine vs. 1ml 
unprocessed urine in paired samples improved diagn stic yield [ 18% (14/38) 
vs. 0% (0/38), p<0.001]. 
 
Conclusions: Use of a grade-2 and not the manufacturer’s suggested grade-1 
cut-point for the urine LAM strip test yields optimal inter-reader agreement, test 
specificity and rule-in utility. In ambulatory primary care patients, urine LAM 
strip testing offers limited diagnostic utility. By contrast, in hospitalized HIV co-
infection with advanced immunosuppression, especially those unable to 
produce sputum, both the urine LAM strip and Xpert MTB/RIF testing, alone or 
in combination, offers important potential clinical utility for rapid rule-in TB 
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The history of humankind has been inextricably linked with tuberculosis (TB), a 
communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). 
Today, TB remains a public health catastrophe affecting the world’s poorest and 
most vulnerable people. Anually, there are almost nine million new cases and 
two million deaths globally [1]. In sub-Saharan African the colliding HIV and TB 
epidemics continue to overburden hospitals and healthcare resources. The lack 
of new TB drugs or an effective vaccine together with the rising threat of multi-
drug and extensively-drug resistant TB, threaten to destabilise the situation 
further [12, 13]. In resource-limited, high TB HIV prevalent settings suboptimal 
and/or delayed diagnosis is one of the major the bottleneck problems hindering 
TB control efforts. HIV, poverty, inadequate laboratory infrastructure and the 
lack of affordable and effective point-of-care diagnostic tools intersect to create 
this bottleneck of suboptimal and/or delayed diagnosis.  
 
1.1. An urgent need for TB point-of-care (POC) tests 
In the majority of res In the majority of resource-limited settings, the frontline 
TB diagnostic tool remains sputum smear microscopy in both peripheral clinic 
and hospital settings. Front-loaded smear microscopy, considered a POC test, in 
settings of high HIV prevalence has reduced diagnostic accuracy. There is an 
urgent need to develop affordable, simple point-of-care (POC) methods that are 
effective in resource-limited, high TB HIV prevalent settings. Recommended 
specifications for a TB POC test are shown and summarised in table 1.0 [11, 14]. 












skills, rapid and applicable in the resource-limited settings such as Sub-Saharan 
Africa.  
 
Table 1.0 Some of the minimum specifications for  TB POC diagnostic tests that need urgent development 
[10, 11]. 
 
Test Specification Minimum Required Value 
Medical decision Treatment initiative 
Time to results  3 hours max. (patient must receive results the same day) 
[Desirable would be <15min] 
Throughput 20 tests/day, minimum, by 1 lab staff 
Specimen type Adults: urine, oral, breath, venous blood, sputum 
[Desired: NON sputum-based sample type and use of finger prick 
instead of venous blood] 
Children: urine, oral, capillary blood (finger/heel prick) 
Sample preparation - 3 steps max. 
- Safe: biosafety level 1 
- Ability to use approximate volumes (ie, no need for precise 
pipetting) 
- Preparation that is not highly time sensitive 
Number of samples One sample per test 
Readout - Easy-to-read, unambiguous, simple “yes”, “no”, or 
“invalid” answer 
- Readable for at least 1 hour 
Waste disposal - Simple burning or sharps disposal; no glass component 
- Environmentally acceptable disposal 
Controls - Positive control included in test kit 
- Quality control simpler and easier than with SSM 
Reagents - All reagents in self-contained kit 
- Kit contains sample collection device and water (if needed) 
Storage/stability - Shelf life of 24 months, including reagents 
- Stable at 30°C, and at higher temperatures for shorter time 
periods (to be defined) 
- Stable in high humidity environments 
Instrumentation - If instrument needed, no maintenance required 
- Instrument works in tropical conditions 
- Acceptable replacement cost 
- Fits in backpack 
- Shock resistant 
Power requirement  Can work on battery 
Training - 1 day max. training time 
- Can be performed by any health worker 
Cost  <US$10 per test after scale-up  













This study evaluates urine-based diagnostic tests that have a potential to 
function as TB POCs in immune-suppressed HIV/TB coinfected patients who 
are either hospitalised or ambulant patients reporting to peripheral clinics in 
resource limited settings such as the Sub-Saharan Africa.  
 
1.2. POC test characteristics for different settings 
An ideal POC test should be both a good rule-in and rule-out test. However, no 
TB test is yet to meet these requirements for different forms of TB disease and 
different clinical settings [10]. Consequently, certain test characteristics are more 
suitable to different clinical settings and levels of the healthcare system. For 
instance, in peripheral, primary care clinics where patients present with less 
advanced TB disease, patient volumes are very high, and available confirmatory 
tests are expensive and time-consuming e.g. TB culture, a POC test with good 
rule-out value (i.e. a screening test) is required [11]. This would allow for 
confident, rapid screening and discharge of non-TB patients together with the 
triaging of patients for doctors’ review and screening with diagnostic tools with 
better specificity [11]. By contrast, in hospitalized patients with more advanced 
disease burden where the need to rapidly and appropriately commence 
treatment is paramount, a rapid rule-in POC test would be preferred [15]. A 
good rule-in test, with high specificity would prevent the unnecessary 
administration of potentially toxic therapies, while at the same time allowing for 
early commencement of life-saving treatment [15]. 
 
1.3. TB Epidemiology and the impact of HIV 
 
The global distribution of new TB and HIV cases are shown in figure 1.1 and 
1.2. South Africa has the fifth highest incidence of TB globally and 













Figure 1.1.  Estimated TB incidence rates, 2010 [1].  
 
 













The colliding epidemics of HIV and TB in sub-Saharan Africa profoundly 
affect the clinical management and public health control of both conditions 
[17]. HIV-infected persons, regardless of level of immunosuppression, are at 
increased risk for developing active TB [16-18]. TB-related mortality is higher 
amongst HIV co-infected people, and TB remains the leading cause of death 
amongst HIV-infected people [19]. With advancing immunosuppression, the 
clinical presentation of TB becomes atypical with an increase in smear-
negative, extra-pulmonary and disseminated forms of TB disease [13]. 
Consequently, TB diagnosis using conventional diagnosis is particularly 
challenging amongst HIV-infected persons and sub-optimal [20].  
 
1.1. Sputum-based TB diagnostics in resource-limited and high HIV-
prevalent settings 
 
1.1.1. Smear microscopy 
 
Smear microscopy remains the cornerstone of TB diagnosis in the majority of 
high burden settings. It is a quick, inexpensive, and specific method for TB 
diagnosis with a sensitivity of up to 80% in immunocompetent patients [21]. 
Unfortunately, it has several drawbacks including: i) decreased sensitivity (as 
low as 20%) in HIV co-infected patients, ii) very low performance in pauci-
bacillary EPTB (<5% sensitivity in pleural, CSF and pericardial fluids), and 
iii) does not allow for drug susceptibility testing [21, 22]. Despite extensive 
efforts to optimize smear microscopy, including the use of concentration, 
bleaching, fluorescent staining and LED microscopy, performance remains 













1.1.2. Chest x-ray (CXR) 
 
Chest x-ray (CXR)is often the only adjunctive TB diagnostic tool available to 
clinicians at hospitals in high burden settings, and is often used to make 
empiric treatment decisions. However, the sensitivity and specificity of CXR 
for TB diagnosis in different settings is highly variable. Several factors such 
as HIV status, primary clinic or hospital setting, experience of CXR reader 
and even the sex of the patient contribute to the variability of the CXR 
performance [24]. Notably, in HIV co-infected patients who are severely 
immune-compromised the radiographic appearances of TB can be atypical 
or absent, with one study showing up to 32% of active TB cases with a 
normal CXR [23]. Furthermore, the poor specificity of CXR means that a 
number of patients are inappropriately treated with anti-TB treatment with 
intendant morbidity. The need for a definitive microbiological diagnosis 
remains. 
 
1.1.3. M. tuberculosis culture 
 
M. tuberculosis culture (Figure 1.3), is considered the reference standard 
diagnostic tool for TB [25]. Some studies across Africa showed that culture 
can detect active pulmonary tuberculosis (PTB) and extra-pulmonary TB that 
was shown to be negative by smear microscopy [26]. However, the culture 
method is limited by the extremely slow growth rate of the M. tuberculosis, 
taking 4-6 weeks for results to be available, thereby limiting its utility for 
clinical decision-making and/or delaying the commencement of treatment 
[27]. Additionally, in HIV-infected patients often presenting with pauci-













Fig.1.3. Culture on Lowenstein-Jensen medium revealed typical dry, heaped-up yellow to buff-coloured 
colonies of Mycobacterium tuberculosis [3]. 
Finally, the performance of culture requires adequate laboratory infrastructure 
and trained microbiology personnel to limit contamination rates [28]. 
Laboratory infrastructure and human resources remain limited in resource poor 
high TB burden settings [6]. 
 
1.1.4. Novel molecular diagnostics 
 
Polymerase chain reaction (PCR) methods that identify specific sequences of 
M. tuberculosis DNA or rRNA are exciting new tests for TB diagnosis and are 
known as nucleic acid amplification tests (NAATs). A number of commercial 
NAATs are widely available and utilised for TB diagnosis. PCR has been , as 
early as 1991, to be very useful in amplifying and detecting DNA fragments 
of M. tuberculosis from uncultures clinical samples such as cerebral spinal 












PCR had much higher sensitivity than any other method, such as microscopic 
visualization or DNA hybridization that were used in the direct detection of 
M. tuberculosis [29]. However, PCR involves the use robust infrastructure that 
requires highly sterile environments, highly skilled personnel and also highly 
bio-hazard material. Nevertheless, another study by Orallo et al () also 
demonstrated the useful and potential role of PCR in the detection of 
M.tuberculosis using EPTB samples such as CSF, pleural fluid, synovial fluid, 
pericardial fluid, urine, bone marrow aspirate, tissue biopsies etc {Rhoda 
Lynn C. Orallo, 2008 
 #1018}. In this study they showed that although PCR had higher sensitivity 
than most of the methods in the diagnosis of TB, the method had low 
Specifity that was associated with false results from non-tuberculous 
infections and other contaminants {Rhoda Lynn C. Orallo, 2008 
 #1018}. A more rapid user-friendly realtime PCR that can be used with little 
skill and reduced bio-hazard is now available yet producing results with 
higher sensivity and specificity. 
1.1.5. Xpert MTB/RIF 
 
Xpert MTB/RIF assay is a real-time PCR platform with excellent sensitivity, 
specificity and low indeterminate rate which can provide a result in less than 
two hours. It is the most exciting new TB diagnostic developed in decades. 
The Xpert MTB/RIF assay integrates DNA extraction, genomic amplification, 
and semi-quantitative detection of M. tuberculosis complex and rifampicin 
(RIF) resistance into a fully automated system [25, 30, 31]. Table 1.1 highlights 
the superior diagnostic accuracy of Xpert MTB/RIF compared to smear 
microscopy to the diagnosis of pulmonary TB [32]. Based on this data, in 
December 2011, the World Health Organisation (WHO) endorsed the Xpert 
MTB/RIF assay for use in the investigation of pulmonary TB and MDR-TB. 












used for frontline TB diagnosis in HIV-infected patients and MDR-TB 
suspects [32]. On world TB day last year, the South African Health minister 
announced that South Africa will replace smear microscopy with the Xpert 
MTB/RIF assay for frontline TB diagnosis [33].  
Table 1.1. Summary of Xpert MTB/RIF sensitivities in comparison to smear microscopy. The findings 
were based on demonstration studies involving 6,673 individuals prospectively enrolled in six 










Single smear /culture positive 
patients 
99 59.5 
Overall culture positive patients 91 59.5 
47 in HIV coinfection 
Smear negative patients >80 n/a 
HIV positive TB patients 86 47 
HIV negative TB patients 92 65 
*MDR confirmed patients 
(Rif resistance) 
95.1 n/a 
*Specifity was 98.4% rifampicin detection 
 
However, despite the promising results of the sputum-based Xpert MTB/RIF, 
it does not solve a number of important diagnostic challenges and many 
obstacles remain to its widespread implementation.  
 
1.1.5.1. Xpert MTB/RIF and EPTB 
Xpert MTB/RIF is dependent on an adequate sputum sample and is hence, 
ineffectual in sputum scarce patients [6]. Limited available data suggests that 
Xpert MTB/RIF has sub-optimal sensitivity in non-sputum biological fluid 
for the diagnosis of EPTB, although no studies have adequately evaluated its 
performance using urine [8, 34]. Table 1.2 shows some of the studies on Xpert 












shown in table 1.2 that assessed the use Xpert MTB/RIF in EPTB made use of 
EPTB specimens that were obtained from non-pulmonary sites from which 
samples are invasive, bio-hazardous and difficult to extract. A few studies 
evaluate performance on urine specimens and numbers of patients are small 
[8, 35]. Hence, there is an urgent need for a larger study to evaluate the 
effectiveness of urine Xpert MTB/RIF in the diagnosis of EPTB. Furthermore, 
despite efforts to reduce test cost, Xpert MTB/RIF remains unaffordable in 
many high burden resource-limited settings [6, 36].  There remains a need for 




























Table 1.2 shows a summary of the studies in which the diagnostic accuracy of Xpert MTB/RIF for 
EPTB was assessed [37] . 
 





Tortoli et al. 
(2012) 
 
Italy Tissue biopsies/fine-needle 
aspirates (94); pleural fluid 
(18); gastric aspirates (61); pus 
(55); CSF (14); urine (16); 
peritoneal/ 
synovial/pericardial fluid (10) 
 
81.3 (76.2–85.8) 99.8 (99.4–100) [35] 
Armand et al. 
(2011) 
 
France LNs (16); pleural (7); bone (5) 53.1 (34.7–70.9) NA [38] 
Causse et al. 
(2011) 
Spain Tissue biopsies (18); CSF (6); 
gastric aspirates (8); pleural 
fluid (4); purulent exudates (5) 
95.1 (83.5–99.4) 100 (98.8–100) [39] 




Pleural fluid (25) 
 
25.0 (8.7–49.1) 100 (47.8–100) [40] 
Hillemann et 
al. (2011) 
Germany Tissue (30); gastric aspirat  (8); 
urine (5) 
77.3 (60.5–87.1) 98.2 (96.0–98.9) [8] 




Fine-needle aspiration LN 
biopsy 
96.6 (86.6–100) 88.9 (69.6–100) [41] 
Moure et al. 
(2011) 
Spain All smear-negative. Pleural 
fluid 
(26); LNs (34); abscess 
aspirates 
(17); tissues (12) 
58.3 (48.5–67.8) 100 (91.4–100) [30] 
Vadwai et al. 
(2011) 
India Tissue biopsies (105); pus (98); 
body fluids (24) 
80.6 (75.5–85.0) 99.6 (97.8–100) [42] 
      
 
1.2. Extrapulmonary Tuberculosis (EPTB) and HIV-coinfection 
 
EPTB is TB disease affecting organs other than the lungs, and the most common 
forms include body cavity (pleural, pericardial and ascitic), lymph node, and 
meningeal [43] . EPTB is responsible for 10-20% of global TB cases  and has 
increased substantial in areas of high HIV prevalence as the incidence of EPTB 














The diagnosis of EPTB is particularly difficult and is the most important obstacle 
to improved management. Both conventional and novel sputum-based 
diagnostic tools such as smear microscopy, Xpert MTB/RIF and M. tuberculosis 
culture have reduced diagnostic accuracy [44]. Consequently, diagnosis often 
requires invasive, expensive tissue sampling for histologically diagnosis and to 
improve the likelihood of microbiological confirmation [45]. Table 1.3 gives a 
summary of the major forms of EPTBs indicating the nature of specimen needed 
for diagnosis and current frontline diagnostic method being used by most 
settings especially resource-constrained settings. Empiric treatment based on 
clinical and radiological screening is commonplace in the management of EPTB, 
and novel non-sputum based diagnostics and diagnostic strategies are urgently 




















Table 1.3. Summary of the major forms of EPTB and their possible diagnostic methods in use in most settings. 
Type of EPTB Percentage 
cases of 
EPTB  
Site of Infection Nature of specimen Possible diagnostic methods 






-Discrete and firm nodes 
Fine needle aspiration biopsy 
(FNAB) 
-Acid fast bacillus stain (AFB) (Zielh-Nelseen stain or 
Papanicolaou stain induced florescence microscopy) [41] 
Culture of FNAB 
Skeletal TB 
[47] 
1-3% of TB 
population 
10% [43] -joints, bones 
-tuberculous arthritis e.g. Of 
hip and knee 
-vertebral column [48] 
-FNAB 
-bone biopsy 
-ZN stain microscopy and 
Culture of FNAB [48] 
TB of the central 
nervous system 
(CNS) [46] 
5% [43] -intracranial 
-meninges tissue 
-spinal chord 
-Cerebral spinal fluid (CSF) -CSF AFB smears 
-CSF M. tuberculosis culture 
-Pelleting of CSF increases culture and smear results. 
Abdominal TB 
[46] 
3% [43] -peritoneal, gastro-intestinal 
tract (GIT), liver, spleen etc. 
-histopathological biopsies -AFB smear and M. tuberculosis culture of biopsy tissue. 
Miliary TB [49] 8% [43] -widespread dissemination 
throughout the body due to 
delays. 
-Broncho alveolar lavage (BAL), 
gastric washings, blood, liver 
biopsy, bone marrow, 
peritoneum etc. [49] 
-Culture and all other diagnostic methods 
Pericardial TB 
[43, 46] 
1-2% [50] -visceral or parietal 
pericardium. 
-Pericardial fluid, pericardial 
biopsy 
- AFB smears, ZN staining on pericardial biopsy, TST, 
Biochemical analysis, M. tuberculosisculture on biopsy, PCR. 
Pleural TB 
[43, 46, 51] 
20% [43] -Pleural fluid, pleural space. -Pleural fluid, pleural biopsy, 
fragments of peritoneum. 
-Cytological examination (ZN and Giemsa stain), PCR, TST, 
M. tuberculosis culture on biopsy (after centrifugation), 
biochemical analysis. 
TB ascites [43, 46] 2% [52] -Ascitic fluid, peritoneal 
cavity 
-Ascitic fluid, peritoneal biopsy -Cytological examination (ZN and Giemsa stain), PCR, TST, 
M. tuberculosis culture on biopsy, biochemical analysis 
Genito-urinary TB 
[44] 
9% [43] Kidney, urinary tract, bladder, 
etc. 













1.3. Urine for TB diagnosis 
 
Urine as a biological sample for diagnostic testing is appealing. Urine is easy to 
collect, readily available and has a low infection risk to staff during collection 
[53]. Urine antigen detection is the most common diagnostic technique 
employed for infectious diseases, and TB diagnosis is no exception [54]. A 
number of M. tuberculosis antigens have been evaluated in urine for the TB 
diagnosis [54]. Of these 12 evaluated TB antigens, lipoarabinomannan (LAM) is 
the most extensively evaluated and promising [54]. 
 
1.3.1. Urine lipoarabinomannan (LAM) for TB diagnosis 
 
LAM is a heat-stable 17.5kD glycolipid that forms one of the main 
components of the outer cell wall of mycobacterial species, and is a 
heterogeneous immune-reactive glycoconjugate [4]. It accounts for up to 15% 
of the total bacterial weight and is an important virulence factor of M. 
tuberculosis [55-57]. LAM consists of three distinct structural domains, 
including a phosphatidylinositol (PI) anchor, a branched mannan, and a 
branched arabinan [58]. Figure 1.4 shows the M. tuberculosis cell wall 















Fig 1.4. A simplified illustration of the M. tuberculosis cell wall showing 
Lipoarabinomannan [4]. 
 
There are three types of LAM namely mannose-capped LAM (ManLAM), 
phospho-myo-inositol capped LAM (PILAM) and non-capped arabinose 
LAM (AraLAM) [59]. The different types of LAM capping determines the 
ability of LAM to modulate immune responses; ManLAM (simply referred 
to as LAM) is the commonest form in M. tuberculosis and is a very potent 
anti-inflammatory molecule and virulence factor [59]. The  mannose caps, 
as recently discovered, may be involved not only in attenuating host 
immune response, but also in mediating the binding of mycobacteria to 
and subsequent entry into macrophages [60]. ManLAM is postulated to 
modulate a number of host responses including: cytotoxic oxygen free-
radical scavenging; inhibition protein kinase C activity and; prevent the 
interferon gamma transcription in macrophages and T-cells. The inhibition 
of macrophage activation, abrogation of T-cell activation and blockage of 
the cytocidal activities contributes immensely to the persistence of M. 
tuberculosis within the mononuclear phagocytes and their dissemination to 
other parts of the body. This shows that ManLAM, which also possesses 













to other types of LAM) is an immunogenic virulence factor of much 
clinical and diagnostic significance [61, 62]. 
 
1.3.2. Detection of LAM in the urine 
 
LAM can be detected in the urine of patients with active TB. This heat-stable 
glycolipid travels in the bloodstream and passes through the renal filtration 
barrier without major changes and is thus detectable in an antigenically intact 














Figure 1.5. Annotated diagram illustrating the passage of mycobacterial DNA and lipoarabinomannan 
antigen from infection site to Urine LAM [4]. 
 
 
Hamasur and colleagues developed an ELISA detection method using a 
polyclonal antibody. Preliminary studies showed that LAM was detectable in 
mice urine injected intraperitoneally with a crude cell wall preparation of M. 
tuberculosis  and the methods were highly sensitive, detecting LAM at 
concentrations of 1 ng/ml and 5 pg/ml [63].  In 2005, the pre-commercial 
prototype of the LAM ELISA (M. tuberculosis LAM ELISA Test®, Chemogen, 













commercial version was superceded by a second generation, commercially-
available prototype known as the Clearview® TB ELISA, (Inverness Medical 
Innovations, USA). The test currently retails as the TB LAM ELISA (Alere, 
USA).  
 
1.3.3. LAM ELISA test performance 
 
The TB LAM ELISA-kit has been extensively evaluated for the diagnosis of 
TB. The majority of studies evaluate performance using urine as the 
biological sample of choice [4]. However, researchers have, with little success, 
investigated the diagnostic utility of the LAM ELISA on other biological 
fluids like serum [64], sputum [65], cerebro-spinal fluid (CSF) [66] and pleural 
fluid [65, 67]. Table 1.4 outlines the evaluations of the urinary LAM ELISA to 
date. Apart from the early studies of by Boehme and Tessema [5, 68], the 
overall sensitivity of urine LAM ELISA has been poor ,ranging from 13-51%, 
for the routine diagnosis of TB [9, 67, 69, 70] . However, amongst HIV-
infected patients with advancing immunosuppression (lower CD4 cell 
counts) and hospitalized in-patients with higher burdens of disease, urine 
LAM ELISA sensitivity improves [4]. Shah et al. (2009), in a South Africa 
hospitalised cohort study showed a sensitivity of 85% in TB HIV co-infected 
patients with a CD4<50 cells/ml [71]. In addition, and of particularly clinical 
importance, in this same study the sensitivity of urine LAM amongst sputum 
smear-negative patients was 56% (Table 1.4) [71]. Thus, urine LAM testing 
seems to offer the greatest potential utility in the diagnosis of TB in HIV co-
infected patients with advancing immunosuppression [45]. This is 
particularly useful given that sputum-based conventional and novel 
diagnostic tools perform poorly, EPTB and disseminated TB is more common 














Table 1.4. Performance of standardized urine lipoarabinomannan assays in different clinical subgroups of patients with suspected tuberculosis stratified by HIV status and, where 







































TB cases (n) 
(n= S-ve, C+ve) 








OVERALL      80 
HIV+               81 










(n=50)  76 (N/R) 
N/R 
N/R 






OVERALL     18 (9-33) 
HIV+              20 (1-77) 










(n=12)   25 (4-64)           
N/R 
N/R 






OVERALL     51 (38-63) 
HIV+              62 (47-75) 










(n=21)    38 
(N/R) 
42 (N/R) 






OVERALL     44 (36-54) 
HIV+              52 (43-62) 










(n=40) 28 (13-43) 
N/R 
N/R 






OVERALL      13 (8-19) 
HIV+              21 (11-35) 
CD4<200        37 (19-59) 
   99 (97-100) 
    100 (91-100) 







(n=70) 3 (N/R) 
18 (N/R) 
25 (N/R) 








OVERALL     38 (27-51) 
HIV +             38 (27-51) 
CD4 50-100    41(22-64) 
CD4< 50         67 (44-84) 
 100 (N/R) 





















OVERALL     59 (52-66) 
HIV+              67 (59-74) 
CD4 50-100    71 (51-87) 























OVERALL     32 (16-52) 
HIV+              32 (16-52) 
CD4 <200       35 (16-57) 













(n=19)  16 (4-40) 
(n=19)  16 (4-40) 
N/R 
N/R 







OVERALL     65 (53-76) 
HIV+              65 (53-76) 
CD4 50-200    67 (43-85) 





























1.4. The LAM lateral flow strip test 
 
Excitingly, Alere Medical innovations has recently developed a simple lateral 
flow format of the Clearview TB LAM ELISA using the same polyclonal 
antibody coupled to gold nanoparticles [6, 19]. The Determine-TB LAM Ag strip 
test (Alere, USA) (figure 1.8), the first truly point-of-care TB test, requires just 
60l of unprocessed urine, can be performed at the patient bedside without the 
need for laboratory skills or electricity and at a likely cost of less than US$3.50 
[6]. Urine is placed on to the loading platform, and after just 25mins the test is 
read using the manufacturer’s provided reference card to interpret band 
intensity. The presence of a band in the control window indicates a valid test, 
and then the colour intensity of the band in the patient window is matched to 
the reference card and graded intensity 0-5 (figure 1.8). Thereafter, the 
manufacturer and reference card categorises patients with a grade 0 bands as 
test ‘negative’ and a grade-1 or higher band as test ‘positive’. This simple test 















Figure 1.8. The LAM strip and reference scale card (graded 0-5 depending on band intensity) that were 
used in the reading of urine LAM results. Grade-1 cut-point considers ‘0’ as negative and 1-5 as positive 
while grade-2 cut-point takes ‘0 and 1’ as negative and 2-5 as positive [6]. 
 
1.4.1. Urine LAM strip test initial diagnostic accuracy evaluation  
 
To date, the urine LAM strip test has only been evaluated in two studies. The 
first in an out-patient antiretroviral clinic setting where the test was used for TB 
screening patie ts prior to the initiation of antiretroviral therapy irrespective of 
symptoms [19], while the second was a cohort of hospitalised patients with 
suspected TB HIV co-infection [6].  
 
1.4.2. Urine LAM strip test for TB screening pre-HAART 
 
The evaluation of the Determine TB-LAM test strips by Lawn et al (2012) in 
outpatients that were being screened for antiretroviral therapy at a primary care 













using the manufacturer-recommended suggested grade-1 cut-point; they found 
a sensitivity and specificity of 28.2% and 98.6% respectively. Sensitivity 
consistently improved with advancing immune-suppression, increasing to 39% 
and 51.7% in patients with CD4<200 and CD4<100 cells/ml respectively [19]. As 
expected, urine LAM strip test diagnostic accuracy was found to be similar to 
that of the urine LAM ELISA assay performance [69, 71]. Furthermore, the inter-
reader reliability between two readers was found to be excellent (K=0.97), but it 
was noted that the median LAM ELISA optical density of urine LAM strip 
positive samples was 0.681 (IQR 0.164–2.431; range 0.102–3.291) meaning that 
few grade-1 positive samples were present in the patient cohort [19]. The 
effectiveness and utility of the LAM strip test is dependent on its high specificity 
which other studies working with the ELISA version showed [67, 73]. The 
performance and utility of the LAM strip test was also evaluated by other 
studies and was found to be promising. 
 
1.4.3. Urine LAM strip test in hospitalised TB HIV co-infection 
 
Peter et al (2012) recently evaluated the diagnostic accuracy of the urine LAM 
strip test for TB detection in hospitalised patients with suspected TB HIV co-
infection and severe illness. Overall using the manufacturer’s suggested grade-1 
cut-point and a composite reference standard, urine LAM strip sensitivity and 
specificity was 66% and 96% respectively. However, inter-reader reliability was 
found to be only moderate using the grade-1 cut-point and in addition, amongst 
a non-TB control group, test specificity and positive predictive value (important 
for rule-in test utility) was reduced using the grade-1 versus the grade-2 cut-
point [6]. Hence, this study recommended the use of a grade-2 and not the 
grade-1 cut-point to optimize the rule-in utility of the test [6]. Sub-group 
analysis indicated that the urine LAM strip test performs best in patients with 













diagnosis of  EPTB [6]. Furthermore, in the clinically important smear-negative 
or sputum scarce (SN/SS) HIV-coinfected patient sub-group the urine LAM 
strip test sensitivity was 38% increasing to 49% in patients with CD4≤ 100 
cell/ml [6]. 
 
Both the out-patient and in-patient studies of the urine LAM strip test showed 
promising results, but important differences were found. Most notably, the 
optimal urine LAM strip test cut-point requires further clarification. Possible 
explanations for the differences in study findings include study populations 
differences, batch variability, reader experience and/or blinding procedures, 
and duration and stability of LAM strip tests during storage [6]. 
 
1.4.4. LAM strip test as and adjunctive diagnostic test 
 
Urine LAM strip testing is unable to offer microbiological confirmation and/or 
drug susceptibility testing. Furthermore, studies of urinary LAM show only 
modest to good overall sensitivity even amongst HIV-infected patients with 
advanced immunosuppression [6, 19, 45]. Thus, urine LAM strip testing will 
likely function as a diagnostic adjunct to existing, largely sputum-based 
conventional and novel rapid TB diagnostics such as smear-microscopy or Xpert 
MTB/RIF [45]. In line with this rationale, both Peter et al (2012) and Lawn et al 
(2012) evaluated the combined performance of urine LAM and either sputum 
smear-microscopy or Xpert MTB/RIF [6, 19]. Interestingly, in both out-patient 
and in-patient cohorts the combined sensitivity of sputum smear-microscopy 
and urine LAM strip testing was significantly higher than the use of each test 
alone [6, 19]. In addition, Lawn et al (2012) found that combined sputum-based 
Xpert MTB/RIF and urine LAM strip testing was not significantly better than 
sputum Xpert MTB/RIF alone [19]. However, the sub-group of sputum scarce 













of sputum induction to aid sample acquisition. Sputum induction is not readily 
available in the majority of primary care clinic settings [6, 45]. The use of urine-
based Xpert MTB/RIF in sputum scarce patients was not evaluated in either 
study.  
 
1.5. Is the urinary LAM specific for M. tuberculosis? 
 
Notwithstanding that the urinary LAM is the most promising point-of-care 
(POC) diagnostic test; there still remains the major setback of cross reactivity 
with other microorganisms that have LAM-like glycolipids, thereby increasing 
the possibility of false positive LAM results. Although LAM is a 
lipopolysaccharide specific to the genus Mycobacteria, it is interesting that LAM-
like glycolipids are also found in several species of fungi and bacteria and these 
are likely to cross-react with LAM antibodies [74].  
 
1.5.1. Possible cross-reactions with polyclonal anti-LAM antibody 
 
Several studies have shown and reported that NTMs and other microorganisms 
can cross-react with polyclonal anti-LAM antibody leading to the LAM assays 
failing to be specific for M. tuberculosis only [67]. Thus far, Boehme et al. (2005) 
has shown in vitro that the LAM ELISA can cross react with non-tuberculous 
mycobacterial (NTM) species although higher NTM colony counts are required 
to produce LAM ELISA optical density above the cut-point for test positivity [5]. 
Gram-positive and Gram-negative samples were prepared with bacterial 
concentrations higher than those in the normal infections yet none showed any 
reactivity in the LAM-ELISA system [5]. Boehme et.al (2005) pre-clinical 
evaluation of the LAM-ELISA using a variety NTMs and other bacteria is shown 

















Figure1.8. (A) No binding of LAM antibodies to Gram-positive and Gram-negative bacteria: Klebsiella 
pneumoniae, Streptococcus agalactiae, Streptococcus pneumoniae 14/12F, Pseudomonas aeruginosa, Staphylococcus 
aureus 25923/43300, Proteus vulgaris, Escherichia coli 8739, Neisseria meningitidis A/B/13102, Haemophilus 
influenzae A/B/D. (B) Reactivity of the listed NTMs in the LAM-ELISA. (C) Sensitivity of LAM-ELISA for 
increasing concentrations of LAM in urine [5]. 
 
G. bronchialis demonstrated presence of substantial LAM-like lipoglycan 
arabinose content and showed cross-reactivity with polyclonal anti-LAM 
antibody [75]. Furthermore, Dheda et.al (2010) carried studies on the possibility 
of mouth flora cross-reacting with polyclonal LAM antibodies in the LAM 
ELISA assay [67]. They used sputum samples from non-TB patients and tested 
cultures and culture supernatants of the specific organisms composing both 
pathogenic and normal mouth flora, especially those possessing LAM-like 
lipoglycans in their cell walls e.g. Nocardia and Streptomyces species (strain-
typed where possible), C.albicans, T. paurometabolum, and Candida neoformans 
[67]. The results which they obtained are shown in Figure 1.7. The study 













samples but the specificity was very low possibly because of cross-reactivity 
with LAM-like microbial lipopolysaccharides in the cell walls of several mouth-
residing organisms such as Candida (also found in genitals), and many species 



























Figure1.7. Dheda et al (2010) demonstrated LAM positivity in cultures of oral flora and in organism-specific cultures such as various Actinobacteria, including different 













These NTMs and other opportunistic pathogens such as Candida species 
could cross-react with the polyclonal LAM antibodies within the assay 
[54]; thereby likely to culminate into false positive LAM ELISA results. 
This creates the need for the development of a standardized method for 
urine sample collection to maintain sample sterility; for this will 
significantly decrease the rate of false positive urine LAM ELISA/lateral 
flow tests. 
1.5.2. Use of a standardized urine sample collection 
methodology 
 
Since a false-positive urine LAM test is likely to be caused by 
environmental contamination or unrelated infections (colonization or 
disease by non tuberculous mycobacterial or fungi), there is a need to 
establish a standardized urine sample collection methodology [67]. This is 
important, and is done in order to maintain sample sterility, thus it will 
likely significantly decrease the rate of false positive urine LAM 
ELISA/lateral flow tests. The importance of preventing contamination by 
normal vaginal, perineal and anterior urethral flora cannot be 
overemphasized and remains the responsibility of the laboratory to 
provide the patient with sterile, wide-mouthed glass or plastic, jars, 
beakers or other suitable receptacles which should have tight-fitting lids 
[76]. Suprapubic aspiration urine collection method is the gold standard; 
unfortunately the method is not practical in many cultural settings. 
However, whenever possible, urine specimen should be collected in the 
morning, before the patient has voided urine and ensure that  mid-stream 
urine or a clean-catch urine is collected [76]. 
 
There is several urine collection methods that are in use to date that strive 
to eliminate any possibility of contamination thereby improving the 
specificity of the LAM assays. Table 1.5  below shows the WHO guideline 













many health care settings to in order to minimize risk of contamination of 
urine samples. 
Table 1.5. The WHO Regional Office for South-East Asia (2011) listed the following guidelines on 
SOPs for Microbiology [70]. 
WHO guideline on standardised sterile urine collection procedures* 
(The sample is best obtained, if the procedure is properly explained to the patient) 
Urine collection in men 
Instruct the patient to wash hands. 
 
Ask the patient to pull back the foreskin and pass a small amount of urine holding back the fold 
of skin; instruct the patient to pass the remaining urine in a sterile container – this is mid-stream 
urine (MSU). 
Place the lid, secure tightly and rapidly transport to the laboratory. 
If the patient is bed-ridden, the nursing staff can help the patient in the above process. 
Urine collection in women 
 Instruct the woman to wash hands with soap and water before collection of specimen. 
 
Patient should undress in a suitable room, spread the labia and cleanse the vulva and labia 
thoroughly using warm soapy water. 
Rinse with warm water and dry. 
Ask the patient to pass urine, discarding the first part of the stream and collecting MSU in a 
sterile container. 
Transport the sample to the laboratory at the earliest after properly securing the lid. 
Bed- ridden patients can be assisted by the nursing staff. 
Urine collection in in Infant and young children 
Ask the child to drink water or any other liquid. 
Clean the external genitalia and let the child be seated in the lap of the mother/nurse/attendant. 
Encourage the child to urinate and collect the same in sterile container. 
Cover the container tightly and rapidly transport to the laboratory for processing. 
 
*Collection of urine from catheters or bag should be avoided as this does not reflect the accurate picture. A 
reasonable alternative to MSU is the clean catch urine. After periuretheral cleaning the whole urine is 















1.7. Current study: Aims and objectives 
 
The overall objective of this project is to evaluate the use of two novel 
tools for the TB diagnosis using human urine. In an ambulatory patient 
cohort (group 1), the diagnostic accuracy and inter-observer agreement of 
two independent readers for the urine LAM strip test is evaluated in order 
to clarify the optimal cut-point. In a hospitalised patient cohort, the 
combined diagnostic accuracy of urine-based Xpert MTB/RIF and LAM is 
evaluated.  
1.7.1.  Ambulatory patient cohort (group 1)  
 
Hypothesis: The use of a urine LAM strip grade-2 cut-point instead of the 
manufacturer’s recommended grade-1 cut-point will significantly improve 
inter-rater agreement and specificity thereby optimizing rule-in diagnostic 
utility. 
 
Aim 1: To evaluate inter-observer agreement between 2 independent test 
readers grading the urine LAM strip tests. 
 
Aim 2: To assess the diagnostic accuracy of the urine LAM strip test using 
the manufacturer’s suggested grade-1 and an alternative grade-2 cut-
point.  
 
1.7.2. Hospitalised HIV-infected cohort (group 2) 
 
Hypothesis: Amongst hospitalized HIV-infected patients with advanced 
immunosuppression, the combination of urinary LAM and Xpert 
MTB/RIF will offer important, incremental and potentially rapid 














Aim 1: To evaluate the combined diagnostic performance of the urine 
LAM strip test or LAM ELISA and urine Xpert MTB/RIF in HIV co-
infected patients with suspected PTB and/or EPTB and advanced 
immunosuppression. 
 
Aim 2: To evaluate the combined diagnostic performance of the urine 
LAM strip test, LAM ELISA and urine Xpert MTB/RIF in sputum smear-
negative and sputum scarce culture-positive, HIV co-infected patients 


















































CHAPTER 2: METHODS AND MATERIALS 
 




This study evaluated the diagnostic accuracy of three novel TB diagnostic 
tools in human urine: Urine LAM lateral flow strip test (Determine TB®), 
Xpert MTB/RIF assay (Cepheid GeneXpert® System and Clearview® TB 
ELISA, (Inverness Medical Innovations, USA). These diagnostics were 
studied in two patient cohorts: ambulatory patients presenting with TB 
symptoms to three primary care clinics (group 1), and hospitalised 
patients with suspected TB HIV co-infection and advanced 
immunosuppression (group 2). The diagnostic accuracy of each tool, alone 
or in combination, was evaluated using sensitivity, specificity, positive 
and negative predictive values (PPV, NPV). Inter-reader agreement was 
assessed by a comparison of proportional agreement and kappa statistics.  
2.2. Data collection and management 
The integrity of this whole study dependent immensely on the way in 
which data was collected. A lot of effort and quality control were placed 
into every stage of data collection right from the clinics and hospital to the 
laboratory where most of the diagnostic work was done. 
The study involved urine samples as specimens for research. Patient 
recruitment and clinical data collection were done by consultant-led 
groups of attending clinicians, with no association to the study team. This 
helped in the reduction of errors emanating from biases. Research nurses 
who helped in the collection of data were well trained. All the data 
collected at the recruitment sites were carefully recorded in a spreadsheet 
and immediately sent to the data capturers of the Lung Infection and 
Immunity Unit who took professional care of all the research data from 













later, but all the laboratory procedures on the urine samples and data 
collection were done by well-trained senior laboratory research scientists 
who were blinded to the clinical details and disease conditions of the 
patients. Well-designed forms were used to immediately record results 
and all the data from the laboratory diagnosis was recorded and stored in 
a Microsoft Excel spreadsheet and Microsoft Word was used to generate 
tables for further data storage. Not less than two senior scientists were 
involved in the analysis of the results especially the LAM strip test 
procedures. All this was done to ensure that the quality control of data 
was maintained and followed. 
2.2.1. Group 1 prospective cohort patients  
 
The group 1 patient cohort consisted of a consecutive series of 300 
ambulant self-reporting TB suspects (≥18 years of age) presenting to 
Gugulethu clinic, a primary health care facility in Cape Town, South 
Africa (Figure 2.1). Gugulethu Township is a predominantly black African 
disadvantaged community that has a very high HIV prevalence. Patients 
were prospectively enrolled if they had symptoms suggestive of 
pulmonary TB including: persistent fevers, loss of weight, night sweats, 
lack of appetite, generalized fatigue, chest pain and a cough for greater 
than 2 weeks. Enrolled patients were also, after appropriate counselling 
and encouragement, tested for HIV and CD4 count and their results were 
determined and recorded.  Demographic, physical and clinical data was 
taken and recorded for each patient on validated and detailed case record 
forms. A written and signed informed consent was obtained from each 
patient and the study was approved by the University of Cape Town 















Figure 2.1. Study flow for group 1 patient cohort showing TB diagnostic, HIV status and 
CD4 count stratification.  
 
 
2.2.2. Urine collection and storage 
 
A spot urine sample (10-30ml) was collected in a sterile container from 
each patient as soon as possible after recruitment. A urine dipstick test 
(UriCHECK 9, RapiMed Diagnostics, South Africa) was immediately 
performed to assess for protein, blood and leucocytes. All the urine 
samples that were collected from each subject were transported to the 
Lung Infection and Immunity Unit within 3-4 hours for further testing. 
Urine for LAM strip testing was immediately transferred from the sterile 
urine pots into sterile 2ml aliquot and was stored at -20oC for later batched 
testing.  
 
300 TB suspects recruited 
from Gugulethu clinic, South Africa
Eligibility criteria
i. receiving primary health care
ii. symptoms suggestive of pulmonary TB 
and HIV
iii. supply at least one adequate urine sample
iv.  Age >18 years
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2.2.3. Laboratory methods 
 
The urine samples used in the study were stored at -20oC and at the time 
of LAM strip testing the samples were thawed and mixed or vortexed for 
approximately 5 seconds.  After mixing the urine, 60l were carefully 
pipetted onto the loading bay or sample pad of the LAM strip after the 
removal of the protective foil. After 25 minutes, the LAM strips 
read/graded under ambient laboratory lighting conditions, avoiding 
direct sunlight. All strips were graded between 25-35 minutes after urine 
was loaded onto the platform. Two readers, blinded to the clinical details 
of the patients, were involved in the reading and interpretation of results. 
A third reader was present to independently read the LAM strips and the 
results were used as tie-breakers in the case of discrepancies in grading 
between the first two readers, thereby reaching a consensus. A 
manufacturer-provided visual reference scale card accompanied each pack 
of 100 LAM strips to assist readers with the grading of coloured bands. 
Figure 2.2 shows the LAM strip and reference scale card that were used in 
the reading of urine LAM results. The presence of a band in the control 
window indicates that the test is valid; thereafter the presence/absence of 














Figure 2.2. The LAM strip and reference scale card (graded 0-5 depending 
on band intensity) that were used in the reading of urine LAM results [6]. 
 
2.2.4. Grading of LAM strip results 
 
The colour intensity of a bar in the patient window was graded 0-5 using a 
scale reference card as shown in figure 2.2. The manufacturer recommends 
a grade-1 cut-point, which means that the appearance of any complete 
band (grade 1-5) is interpreted as “test positive” while the complete 
absence of a band is interpreted as “test negative”. A broken or incomplete 
bar in the patient window, irrespective of band intensity, is interpreted as 
a “test indefinite” result. The use of the alternative grade-2 cut-point 
suggested by Peter et al (2012) means that the appearance of only a grade 
2-5 band is interpreted as “test positive”, while both the complete absence 
of a band and a grade-1 band is interpreted as “test negative” [6].  
Peter et al selected the grade-2 cut-point to optimise rule-in test utility 
using receiver operating characteristic (ROC) curve analysis shown below 













Figure 2.3. The receiver operator characteristic (ROC) curves that Peter et al (2012) used in 
the LAM strip test grading conducted by 2 independent readers.  Sensitivity, specificity, 
indeterminate rate and likelihood ratios for visual band intensity grade-1 cut-point 
(manufacturer-recommended) and grade-2 cut-point (optimal ‘rule-in’) are indicated [6].    
 
2.2.5. Statistical measures of agreement  
 
In order to interrogate the differences in inter-reader agreement for the 
urine LAM strip testing using different cut-points, both a simple 
proportional agreement. Table2.1 below shows a categorisation scale that 


















Table 2.1. The kappa values and their interpretations. 
Interpretation of Kappa 
Kappa value Agreement 
<0 Less than chance agreement 
0.001-0.20 Slight agreement 
0.21-0.40 Fair agreement 
0.41-0.60 Moderate agreement 
0.61-0.80 Substantial agreement 
0.81-0.99 Almost perfect agreement 
1.00 Perfect agreement 
 
2.2.6. Group 2 prospective cohort patients  
Group 2 study population consisted of a consecutive series of 335 
prospectively recruited adult patients that were recruited from four hospitals (3 
district- and 1 tertiary-level hospital) between 22 July 2009 and 14 December 2010 
in Cape Town, South Africa. There 3 patients  who refused consent and were 
therefore  excluded from the study. This group of patients consisted of 
hospitalized persons with suspected TB HIV co-infection (≥18 years of 
age) presenting to these four district hospitals in Cape Town, South Africa 
(Figure 2.4). Patients were enrolled if they had symptoms suggestive of 
pulmonary TB including: persistent fevers, loss of weight, night sweats, 
lack of appetite, generalized fatigue, chest pain and a cough for greater 
than 2 weeks, and either were known HIV-infected or clinically suspected 
to be. Enrolled patients were, after appropriate counselling and 
encouragement, tested for HIV and CD4 count and their results were 
determined and recorded.  Demographic, physical and clinical data was 
taken and recorded for each patient on validated and detailed case record 













patient and the study was approved by the University of Cape Town 
Human Research Ethics Committee.   
 
 
Figure 2.4. Outline of the study population groups and their breakdown into different TB 
diagnostic. 
 
2.2.7. Laboratory methods 
 
2.2.7.1. Diagnostic sample collection handling  
 The timing and extent of the diagnostic work-up, the beginning of 
empiric anti-TB treatment and the final discharge of patients from the 
hospital were based upon decisions made by consultant-led groups that 
were composed of attending clinicians with no association to the study 
team. However, the TB diagnostic work-up was not standardised, but the 
routine local hospital practice was done; this included collecting two 













if EPTB was suspected, 1-2 non-sputum samples were collected from the 
patients particularly from their clinically involved sites. The site from 
which the EPTB specimens were collected included fine needle aspirate of 
lymph node, pleural fluid aspirate/biopsy, ascitic tap, CSF, pericardial 
aspiration gastric washings and urine. The National Health Laboratory 
Services, a local reference laboratory, processed all clinical specimens 
collected for TB diagnosis. Fluorescence smear microscopy was 
performed on NALC/NaOH processed sputum, which was also cultured 
using the MGIT 960 liquid culture system (BD Diagnostics, USA). The 
reference standard for definite-TB was liquid culture positivity for M. 
tuberculosis [45]. 
 
2.2.7.2. Urine sample collection and preparation 
The urine samples that were used in the urine Xpert MTB/RIF assay were 
collected from patients recruited from the 4 hospitals in Cape Town, 
transported to the Lung Infection and Immunity Unit where they were 
stored and frozen in the -20oC refridgerator. A total of  175 urine samples, 
were collected and prepared to be run on the Xpert MTB/RIF assay; 
113/175 (~65%) samples from M. tuberculosis culture positive patients and 
62/126 (~50%) were randomly selected urines from M. tuberculosis culture 
negative patients as shown in figure 2.4. The selection of urine from M. 
tuberculosis culture negative non-TB patients was random and only about 
half the total number of the available M. tuberculosis culture negative urine 
samples were coolected and prepared for Xpert; this was due to resource 
and time-constraints. This formed our control group which included HIV-
infected TB-culture negative patients which allowed for the evaluation of 
urine Xpert MTB/RIF specificity. The details of the procedure for the 
collection and sample management are described in section 2.1.2.  
However, the actual procedure and preparation of samples for the Xpert 
MTB/RIF assay are described in the next section 2.1.7.1. Some of the urine 
samples were run straight in the Xpert MTB/RIF assay without 













samples that had adequate volumes for centrifuging were processed as 
described in the next sect section. 
 
2.2.7.3. Urine sample pelleting for Xpert MTB/RIF assay 
 
There were 175 urine samples, in total, that were run on the Xpert 
MTB/RIF assay, 113 samples from M. tuberculosis culture positive patients 
and 62/126 randomly selected urines from M. tuberculosis culture negative 
patients. Only urine samples that were between 2ml-10ml were 
considered for pelleting; a total of 43/113 (41%) negative urine samples  
were selected for pelleting, while 13/113 (12%) negative urine samples 
were either insufficient or depleted. The urine samples were first mixed 
thoroughly and a specific volume (see Table 2.3), depending on the 
amount of urine available, was transferred to the blue capped 15 ml 
centrifuge tubes. Centrifugation of urine samples was performed at 3500 x 
g for 15 minutes in the ROTOFIX 32A (Hettich, zentrifugen) or 
BECKMAN COULTER (Allegra™ X-12R Centrifuge). Table 3.2 shows a 
summary of all the negative samples that were pelleted. After centrifuging 
the supernatant was removed using a PIPET.AID® automated pippete 
(Drummond Scientific Co. PA, USA) leaving 1 ml of urine in the tube for 
the resuspension of the pellet. The pellet was resuspended in the 
remaining solution and the 1 ml suspension was used for the Xpert 
MTB/RIF assay using the manufacturer’s instructions as described in 
figure 2.5. The rest of the supernatant and remaining urine samples were 

















Table 2.3. The number and volume of urine samples that were pelleted by centrifuging at 3500 x g/ 
15 minutes. 
 
Volume of urine pelleted 
(ml) 
M. tuberculosis culture-positive 
urine samples pelleted 
(n=43) 
M. tuberculosis culture-
negative urine samples 
pelleted 
(n=30) 
2 2 0 
3 1 0 
5 8 0 
6 1 1 
7 1 0 
7.5 0 1 
8 1 1 
8.5 1 1 




2.2.7.4. Urine Xpert MTB/RIF assay 
 
Principle: The Xpert MTB/RIF assay (Cepheid GeneXpert® System) , 
shown in figure 1.4, is a hemi-nested real-time PCR in-vitro diagnostic test 
that is capable of detecting M. tuberculosis complex DNA in a sample while 
simultaneously detecting rifampicin resistance including a semi-
quantitative assessment of bacillary load. The 15 minute-long step of 
mixing the bactericidal buffer with the sample is the only hands-on step of 
the whole process; this pre-amplification phase renders the M. tuberculosis 
non-viable and harmless as shown in figure 2.5 [78]. All these qualities of 
the Xpert MTB/RIF assay makes it a choice diagnostic tool for near patient 
usage especially in settings with poor bio-containment facilities [78, 79]. 
This process makes use of five overlapping molecular probes 
complementary to the whole M. tuberculosis rpoB gene containing the 81 













all the mutations found in >99.5% of all rifampicin resistant strains 
ensuring that there no cross-reactivity with non-tuberculous mycobacteria 
occurs [32] . If there are at least two of these rpoB probes that are positive 
within two cycles of each other, then the result will be M. tuberculosis 
positive; also if at least a single rpoB probe does not result in a measurable 
signal and/or a presence of a 3.5 cycle or a significant deviation in the 
Cycle threshold (Ct) value between the earliest and latest rpoB signals 
then the system regards that as a RIF resistance result [80, 81]. An 
estimation of 95% of RIF resistant cases arise as a result of mutations 
found in the RRDR [36, 39]. This hemi-nested PCR amplification assay, 
integrated into a single disposable cartridge, depends on six colour 
fluorescent molecular beacons to detect the presence of any amplified 
target [36, 80]. The Xpert MTB/RIF has a robust and full process control, 
that acts as a quality check for bacterial trapping, bacterial lysis, DNA 
extraction, amplification, and probe detection; this process makes use of 
Bacillus globigii, a spore-forming soil organism [82]. 
The Xpert MTB/RIF assay has been found to have a limit of detection 
(LOD) of 131 CFU/ml of sputum [80]. The Xpert LODs for urine and other 
extrapulmonary specimens have not been established yet. This could have 
been a vital piece of information especially in the optimization phase of 
these extrapulmonary specimens for use in Xpert MTB/RIF studies. 
However the performance of Xpert MTB/RIF in sputum as reported by 
the World Health Organisation (WHO) is worth investigating as this gives 
a good forecast of how it is likely to perform in extrapulmonary specimens 
like urine. 
 
Procedure: The Xpert MTB/RIF assay procedure consists of two stages that 
involve the manual preparation of reagents and specimen and an 
automated stage. The manual phase is characterized by a 15-minute 
treatment of the urine samples with a NaOH and isopropanol-containing 













eradicating any possibility of biohazard due to its ability to reduce the 
viability of M. tuberculosis [79, 81]. The urine sample: reagent buffer ratio is 
1:2.  The mixture is transferred manually into a disposable plastic 
cartridge that is preloaded with liquid reagents lyophilized reagent beads 
after which the cartridge is carefully inserted into the Xpert MTB/RIF 
assay machine. The rest of the procedures are automated [36]. Figure 2.5 
summarizes all the steps and procedures of the Xpert MTB/RIF assay that 
should be followed. Sample extraction, amplification and detection of M. 
tuberculosis and RIF resistance is entirely automated and done in a single 
cartridge; and this substantially reduces cross contamination [36]. 
 
 
Figure 2.5. Assay Procedure for the MTB/RIF Test. 2 ml of bactericidal buffer is added to 1 ml of 
well-mixed urine. The resultant mixture is shaken for about 15 seconds, incubated at room 
temperature for 7 minutes, and shaken again and further incubated again for 8 minutes (a total of 
15 minutes). 2 ml of the inactivated sample reagent: sample mixture is then taken out and 
transferred to the disposable plastic MTB/RIF cartridge and loaded into the GeneXpert device. The 
remaining steps that follow are automated. The automatically generated results are ready after 2 
hours and are shown on the monitor screen reflecting whether MTB or RIF resistance have been 














2.2.7.5. Xpert MTB/RIF results interpretation and evaluation 
(adapted from the manufacturer’s instructions) 
 
Results were displayed in the “View Window” of the Xpert MTB/RIF as a 
result of fluorescent signals that are quantitated and processed through an 
embedded calculation algorithm in the Xpert MTB/RIF software. Final 
results come out as MTB NEGATIVE or MTB POSITIVE, with either RIF 
resistance DETECTED, RIF resistance NOT DETECTED or 
INDETERMINATE. In the event that the M. tuberculosis positive result is 
displays RIF resistance DETECTED, or INDETERMINATE, the amplicon 
would be extracted under sterile conditions on ice using an insulin syringe 
and transferred into a PCR appendorf tube and stored at -80oC for later 
sequencing. Repetition of tests were only necessary in the event of results 
that were displayed as “INVALID”, “INDETERMINATE”, “ERROR” or 
“NO RESULT” as these could mean that there was a problem or faulty in 
the way the sample preparation was done or the volume transferred into 
the cartridge might have been too small for processing. Cycle threshold 
(Ct) values were also displayed in the event of a positive result. Ct values 
represented a number of cycles needed for the fluorescent signal to cross a 
given background level or threshold. The Ct values are known to be 
inversely proportional to the amount of target M. tuberculosis DNA in the 
urine sample, hence a lower Ct value are representative of a higher initial 
concentration of the M. tuberculosis in the urine and higher Ct values 
reflect a lower initial concentration in the urine sample. Depending on the 
Ct value of the target M. tuberculosis DNA, positive results are shown as a 
semi-quantitation and displayed as HIGH, MEDIUM, LOW or VERY 

















Table 2.2.XpertMTB/RIF result name and Ct value range 
MTB result Ct range 
High  <16 
Medium   16-22 
Low   22-28 
Very Low  >28 
 
2.2.7.6. Urine LAM ELISA assay 
 
The LAM ELISA assay was not done in this study but the results from the 
previous studies [6] were available for analysis. However, a brief 
description of the principle and procedure of the LAM ELISA is given 
below. 
Antibodies adsorbed on the ELISA plate capture the carbohydrate surface 
antigen found in positive test samples. The conjugated antibodies then 
attach to the captured antigen creating a sandwich assay. In the presence 
of the colour developer, a colour change occurs. The assay reaction is 
stopped using the stop solution, and the intensity of the colour (optical 
density) is measured using a microtiter plate reader. A positive result 
indicates that LAM antigen of mycobacteria is present in the sample, 
whereas a negative result indicates that it is not present or is below the 
test’s detection limits 
(http://www.clearview.com/tb_elisa/frequently_asked_questions.aspx).  
The detailed procedure that was used for the LAM ELISA assay for this 
study has been previously described [67]. However, figure 2.5 below 















Figure 2.6. Flow diagram illustrating the steps of the Clearview TB® -LAM ELISA procedure. 
Urine is first boiled at 95–100°C for 30 min and centrifuged for 15 min at 10000 rpm. The 
supernatant is applied to the plate, an incubated for 60 min at ambient temperature, and 
washed with Phosphate Buffered Saline pH 7.4/Tween-20 (PBST). Subsequently, 0.1ml of 
undiluted conjugate solution (HRP-conjugated LAM-specific rabbit polyclonal antibody) is 
added. After 60 min incubation and washing with PBST, 0.1 ml of the colour developer (TMB) 
is administered to each well. The substrate is incubated again for 15 min at ambient 
temperature, and the reaction is stopped by adding 0.1 ml of stop solution (1 M H2SO4). The 
colour development is then measured at 450 nm [9]. 
 
2.2.8. Statistical analysis 
 
A p value, p<0.05,  was considered significant and the statistical softwares 
that were used to calculate these p-values were MedCalc Software Version 
12.2.1 ( MedCalc Software, Broekstraat 52, 9030 Mariakerke, Belgium) and 
XLSTAT 2012.1.02 (© Addinsoft 1995-2012). Statistical analysis was 
performed using GraphPad prism v5.0a (GraphPad, San Diego, CA, USA). 
Evaluation of the diagnostic test parameters was done using a Diagnostic 













Epidemiologic Statistics for Public Health, Version 2.3. 
www.OpenEpi.com). Definitions for the diagnostic parameters were 
largely taken from MedCalc Software Version 12.2.1(MedCalc Software, 
Broekstraat 52, 9030 Mariakerke, Belgium). 
Inter-reader agreement was analysed using Kappa statistics in the IBM 
SPSS Statistics 20 (SPSS Inc., 233 S. Wacker, 11th Floor, Chicago, IL 60606-
6307) 
 
2.2.8.1. Definition of diagnostic test parameters 
 
Sensitivity: The probability that a test result will be positive when the 
disease is present (true positive rate). 
Specificity: The probability that a test result will be negative when the 
disease is not present (true negative rate). 
Positive predictive value (PPV): The probability that the disease is present 
when the test is positive. 
Negative predictive value (NPV): The probability that the disease is not 
present when the test is negative. 
2.2.8.2. Calculation of the diagnostic test parameters 
The starting point for the calculation of the sensitivity, specificity, PPV 
and NPV was the construction of a 2x2 table with the index test results 
on one side of the table and the reference standard (culture) results on 



















Table 2.4 shows the 2x2 table format that was used to calculate* the sensitivity, 
specificity, PPV and NPV [86] 
 
Reference Standard 
 Disease present Disease absent Total 
Index test positive True positive (TP) False positive (FP) TP+FP 
Index Test negative False negative (FN) True negative (TN) TN+FN 
Total TP+FN TN+FP  
  
*Calculations using the 2x2 table [86] 
Sensitivity = TP/(TP+FN) 
Specificity = TN/(TN+FP) 
Positive Predictive Value (PPV) = TP/(TP+FP) 
Negative Predictive Value (NPV) = TN/(TN+FN) 
There was no manual calculation of diagnostic accuracy parameters; all 
calculations were done using a statistical software called Diagnostic or 
Screening Test Evaluation 1.0 using OpenEpi (Open Source Epidemiologic 
























CHAPTER 3: GROUP 1 RESULTS AND DISCUSSIONS 
 
 
In this chapter, the diagnostic accuracy and inter-rater agreement results 
for the urine LAM strip test in group 1 ambulatory patients is presented.  
 
3.1. Group 1 patient characteristics 
 
Figure 3.1 provides a study outline of M. tuberculosis culture and HIV 
status, together with urine LAM strip test results. 300 participants were 
enrolled for this study and one participant was unable to provide a urine 
sample at the time of enrolment. 96% (287/299) had M. tuberculosis culture 
results. 27% (80/291) were HIV positive. Amongst the HIV positive cases, 
63% (50/80) had CD4 ≤200 cells/ml, and 9% (7/80) had unknown CD4 
count at the time of study. The characteristics and demographics of this 
study are shown in table 3.1. The median (IQR) age of patients was 39 
(IQR: 31-46); and the majority of patients were males (63%) and of African 
race (97%). A greater proportion of HIV-infected compared to un-infected 
patients had a history of TB [54% (95% CI: 43-65) vs. 40% (95% CI: 34-47), 
p=0.04]. Also, there was a significantly larger proportion of males 
uninfected with HIV than those infected [72% (95% CI: 66-78) vs. 40% 
(95% CI: 30-51), p<0.001]. Moreover, there were comparable proportions 
of M. tuberculosis culture positive and culture negative patients with a 
history of TB [45% (95% CI: 30-61) vs. 43% (95% CI: 37-49); p=0.006, 
respectively]. Among patients who reported weight loss, 83% (95%CI: 68-
92) had M. tuberculosis culture-confirmed TB compared to 57% (95%CI: 51-
63) who were M. tuberculosis culture negative, p=0.002. A significantly 
higher proportion of patients with M. tuberculosis culture positive 
compared to culture negative had reported having fever (>38oC) [13% 
(95% CI: 5-26) vs. 2% (95% CI: 1-4), p=0.007]. More so, there were more 













fevers [8% (95% CI: 3-15) vs. 2% (95% CI: 1-5), p=0.03]. There were more 
patients with a CD4 >200 cells/ml compared to patients with CD4 ≤200 
cells/ml in patients who experienced night sweats [87% (95% CI: 68-98) 
vs. 50% (95% CI: 36-64), p<0.002].  
 
 
Figure 3.1. Study flowchart showing TB diagnostic grouping, HIV status, CD4 count grouping and 




































*CD4 >200 cells/ml 
(n=23) 

















Male sex 188 (63) 25 (63) 153 (62) Ɵ152 (72) Ɵ32 (40) 16 (32) 10 (44) 
Race Black 290 (97) 39 (98) 239 (97) 205 (97) 77 (96) 47 (94) 23 (100) 
Coloured 8 (3) 1 (3) 7 (3) 5 (2) 3 (4) 3 (6) 0 (0) 
Other 1 (0.3) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 





264 (88) 37 (92) 216 (87) 189 (90) 67 83) 42 (84) 19 (83) 
Night 
sweats 
147 (49) 33 (83) 194 (79) 168 (80) 65 (82) ɸ25 (50) ɸ20 (87) 
Weight 
loss 
181 (61) ¥33 (83) ¥141 (57) 126 (60) 54 (68) 33 (66) 15 (65) 
Fever 
>38C 
9 (3) €5 (13) €5 (2) ҙ4 (2) ҙ 6 (8) 2 (4) 3 (13) 
 
 
#There were 12 contaminated M. tuberculosis cultures; @8 participants had unknown HIV results; *7 participants had 
unknown CD4 count results 













3.2. Inter-reader agreement 
 
Table 3.2 provides the overall grading agreement for the urine LAM strip 
test. Proportionate agreement was 82% (244/299) with a kappa of 0.52, which 
was moderate. 
 
Table 3.2. Cross-tabulation of urine LAM strip grading between two independent readers  
 










0 204 17 0 0 0 221 
1 30 34 3 1 0 68 
2 0 0 6 3 0 9 
3 0 0 0 0 1 1 
Total 234 51 9 4 1 299 
  *Measure of Agreement, Kappa=0.518 
Table 3.3 shows the cross-tabulation of the urine LAM strip test results for 2 
readers with results dichotomized at using the manufacturer’s suggested 
grade-1 cut-point i.e. grade 1-5 considered test positive and only grade 0 
considered test negative.  The proportionate agreement was 84.3% (95%CI: 



















Table 3.3. Cross-tabulation of urine LAM strip grading between two independent readers using 
dichotomized results at the manufacturer’s recommended grade-1cut-point (Grade0=0; Grade 1-5=1) 
 
 




Reader 1 Total 
Neg Pos 
Reader 2 Neg 204 17 221 
Pos 30 48 78 
Total 234 65 299 
*Measure of Agreement, Kappa = 0.57 
 
Table 3.4 shows the cross-tabulation of the urine LAM strip test results for 2 
readers with results dichotomized at using the alternative grade-2 cut-point 
i.e. grade 2-5 considered test positive and grade 0-1 considered test negative.   
 
Table 3.4. The inter-reader agreement between the two LAM strip readers using our grade-2 cut-point. 
 
 
#Reader2 and reader1 crosstabulation 
Count 
 Reader2 Total 
Neg Pos 
Reader1 Neg 285 0 285 
Pos 4 10 14 
Total 289 10 299 
#Measure of Agreement, Kappa = 0.83 
 
The proportionate agreement between the two readers using a grade-2 cut-
point was 98.7% (95%CI: 97.3-100) (295/299) with a kappa of 0.83. 
Proportionate agreement was higher using the alternative grade-2 cut-point 













98.6% (95%CI: 97.3-100) 295/299 vs. LAM cut-1: 84.3% (95%CI: 80.1-88.4) 
252/299 vs; p<0.001]. 
 
3.3. Inter-reader agreement in HIV-infected patients 
 
Table 3.5 shows that in HIV-infected patients, the proportionate agreement 
between the two readers using a grade-1 cut-point was 84.7% (95%CI: 78.2-
88.1) (180/215) with a kappa value of 0.58 which was moderate. 
 
Table 3.5. Cross-tabulation of urine LAM strip grading between two independent readers using 
dichotomized results at the grade-1 cut-point among the HIV negative subjects. 
 
*Reader1  and  reader2 Crosstabulation 
Count 
 reader2 Total 
Neg Pos 
reader1 Neg 142 23 165 
Pos 12 38 50 
Total 154 61 215 
   *Measure of agreement, Kappa = 0.58 
 
Table 3.6, shows that the overall proportionate agreement between the two 
readers in the HIV negative patients, using grade-2 cut-point, was 98.6% 



















Table 3.6. Cross-tabulation of urine LAM strip grading between two independent readers using 
dichotomized results at the grade-2 cut-point among the HIV negative subjects. 
 
 
*Reader1  and reader2 crosstabulation 
Count 
 reader2 Total 
Neg Pos 
reader1 Neg 203 0 203 
Pos 3 9 12 
Total 206 9 215 
   *Measure of agreement, Kappa = 0.85 
 
The overall proportionate  agreement between the two readers in the HIV 
positive patients, using grade-1 cut-point, was 84.2% (95%CI: 74.4-90.7) 
(64/76) with a kappa value of 0.44 which was moderate, as shown in table 
3.7 below. 
 
Table 3.7. Cross-tabulation of urine LAM strip grading between two independent readers using 
dichotomized results at the grade-1 cut-point among the HIV positive subjects. 
 
 
*Reader1 and reader2 crosstabulation 
Count 
 reader2 Total 
Neg Pos 
reader1 Neg 57 7 64 
Pos 5 7 12 
Total 62 14 76 














In table 3.8 below, the overall measure of inter-reader agreement between the 
two readers in the HIV negative patients, using cut-point 2 was 100% 
(95%CI: 95.2-100) (180/215) with a kappa value of 1.00 which, was a perfect 
agreement. 
 
Table 3.8. Cross-tabulation of urine LAM strip grading between two independent readers using 
dichotomized results at the grade-2 cut-point among the HIV positive subjects. 
 
 
*Reader1 and reader2 crosstabulation 
Count 
 reader2 Total 
Neg Pos 
reader1 Neg 75 0 75 
Pos 0 1 1 
Total 75 1 76 
   *Measure of agreement, Kappa = 1.00 
 
Table 3.9, below, shows that there was a significant difference in the inter-
reader agreement using of cut-point 1 versus cut-point 2 in both HIV positive 
and negative patients. However, there was no significant difference between 























Table 3.9. Different Kappa values and the proportion of the overall agreement between the two 






Kappa values Overall proportional  agreement 
% (95% CI) 
Cut-point 1 Cut-point 2 Cut-point 1 Cut-point 2 P-value 
Negative 
(n=215) 

























*8/299 patients had no HIV results (either refused or unknown). 
# and * refer to the comparison of proportional agreement between HIV negative and positive 
patients within each cut-point; #p=0.94; * p>0.99 
 
3.4. Urine LAM strip test diagnostic accuracy 
 
Table 3.10 shows diagnost c accuracy measures for the urine LAM strip test 
stratified by cut-point. Overall sensitivity, irrespective of cut-point was poor. 
Sensitivity was 25% (95%CI: 14-40, 10/40) and 10% (95%CI: 4-23, 4/40) for 
the grade-2 a d grade-1 cut-points respectively (p=0.09). By contrast, test 
specificity significantly increased from 79.8% (95%CI: 74.3-84.3, 197/247) 
when using the grade-1 to 94.3% (95% CI: 91.0-96.6, 233/247) when using the 
grade-2 cut-point (p<0.001). At a disease prevalence of 13%, the use of the 
grade-2 vs. grade-1 cut-point did not increase PPV [16.7% (95%CI: 9.3-28.0, 
10/60) vs 22.2% (95%CI: 9.0-45.2, 4/18), p=0.647]. Table 3.10 shows the 


















Table 3.10. Diagnostic accuracy of the urine LAM strip test using the manufacturer’s grade-1 and the 
alternative grade-2 cut-points. 
 
 
*Indicates p-values for a comparison of the LAM strip overall performance between grade-1 
and grade-2 cut-points.  
 
3.4.1. Urine LAM strip test diagnostic accuracy in HIV infected patients 
 
Table 3.11 shows diagnostic accuracy measures for the urine LAM strip test 
stratified by HIV status and grade cut-point. In HIV positive patients 
sensitivity did not decrease significantly when using the grade-2 vs. grade-1 
cut-points [5.3% (95%CI: 0.9-24.6; 1/19) vs. 21.1% (95%CI: 8.5-43.3; 4/19), 
p=0.19. However, in HIV positive patients specificity was significantly 
higher when using the grade-2 compared to the grade-1 cut-point [100% 
(95%CI: 93.8-100; 58/580) vs 84.48 (95%CI: 73.0-91.6; 49/58); p=0.009]. More 





Overall performance (N=287) 
Cut-point 1 
 






















































negative patients [100% (95%CI: 93.8-100; 58/58 vs 93.4% (95%CI: 88.8-96.1; 
169/181); p=0.02]. No changes were seen in the NPVs in both HIV positive 
and HIV negative patients when a grade-2 cut-point was used, though there 
was a significant difference in the NPVs between the HIV positive and 
negative patients within each cut-point. 
 
Table 3.11. Diagnostic accuracy of the urine LAM strip test using the manufacturer’s grade-1 and the 




*p=0.009; #p=0.0001; p>0.05 for comparisons between HIV positive or negative grade-1 
cut-point and HIV positive or negative cut-point 2 not indicated. 
P<0.05 for comparisons between HIV positive and HIV negative patients within each 




The urine LAM strip test, when used among ambulant TB suspects 







































































































similar to that of the preceding urine LAM ELISA, even among HIV-
coinfected patients. The use of a grade-2 rather than the manufacturer’s 
suggested grade-1 cut-point optimises rule-in test utility by improved test 
specificity, and furthermore the grade-2 cut-point greatly improved inter-
reader reliability. 
 
These results confirm the findings of Peter et al. (2012), and support the 
preferred use of the grade-2 rather than the grade-1 cut-point [6]. 
Furthermore, the overall poor sensitivity of the LAM strip test in this study is 
similar to that of previous studies that were carried among out-patients, as 
shown in table 1.4, using the preceding urine LAM ELISA. For instance, the 
LAM ELISA sensitivity was 5.8% in one study [87]. In addition, Dheda et al 
(2009) produced an overall sensitivity of 13% using LAM ELISA and a 
specificity of 99%, which is comparable to our LAM strip grade-2 cut-point 
sensitivity and specificity of 10% and 94% respectively [67].  
 
 




































CHAPTER 4: GROUP 2 PATIENT RESULTS AND DISCUSSION 
 
This chapter presents the diagnostic accuracy of urine-based LAM and 
MTB/RIF in a cohort of hospitalised TB HIV co-infected patients with 
advanced immunosuppression. We have examined the sensitivity of urine-
based tests alone or in combination for smear-negative or sputum scarce 
TB.  
 
4.1. Study population 
 
The study population involved a consecutive series of well-defined 116 M. 
tuberculosis culture positive HIV-TB co-infected patients. These patients were 
at least 18 years of age and had illnesses requiring hospitalization; they were 
recruited from 4 hospitals in Cape Town. 3/116 patients were missing urine 
samples. 54/113 (48%) were either sputum smear-negative or sputum scarce 
(SN/SS) [20/54 (37%) sputum scarce and 34/54 (63%) sputum negative]. 


















Figure 4.1. Summary of the study population groups and the diagnostic performance of Urine LAM 
ELISA, urine LAM strip test and urine Xpert MTB/RIF in each the patient group. 
 
4.2 The demographic and clinical characteristics of study patients 
 
The patient demographic and clinical features of the study group stratified 
by sputum smear status, CD4 cell count and Xpert MTB/RIF results are 
shown in Table 4.1.  The median (interquartile range) age was 35 (28-38) 
years and the cohort was predominantly females (59%). In HIV-infected 
patients, the median (IQR) CD4 cell count was 89 (45-195) cells/ml and 75% 
of patients were on ARVs at enrolment. 32/113 (28%) had previous TB and 
25/113 (22%) were current smokers. The commonest symptom was self-
















Table 4.1.  Demographic, clinical and microbiological characteristics of M. tuberculosis culture positive and HIV-infected patients in the study population stratified by CD4 cell count, 
























†no significant differences between patient groups were noted for any of the patient characteristics; #9 patients did not have data CD4 count data  












































Male 47(41) 22 (37) 25 (45) 34 (42) 7 (27) 19 (32) 














Previous TB 33 (29) 19 (32) 14 (25) 21 (26) 8 (31) 19 (32) 
Current Smoker 25 (22) 15 (25) 10 (18) 16 (20) 6 (23) 12 (20) 
Clinical features       
Cough >2wks 99 (85) 54 (90) 45 (80) 68 (84) 21 (81) 50 (85) 
Night sweats 82 (71) 46 (77) 36 (64) 57 (70) 18 (69) 39 (66) 
Weight loss 105 (91) 53 (88) 52 (93) 74 (91) 22 (85) 50 (85) 













4.3. Diagnostic accuracy of sputum smear microscopy and urine-based 
diagnostics 
 
Table 4.2 shows the sensitivity and specificity of sputum-based smear 
microscopy compared to urine-based LAM ELISA, strip test and MTB/RIF. 
When used alone, all included tests offered equivalent overall sensitivity, 
between 48-58%. . Among the urine-based diagnostic methods, MTB/RIF 
had a significantly higher specificity compared with LAM ELISA and LAM 
strip tests [Urine MTB/RIF: 98%, (95%CI: 95-100, 61/62) vs. LAM ELISA: 
89%, (95%CI: 81-97, 55/62); p=0.03 and LAM strip test: 85%, 95%CI: (77-94), 
53/62; p=0.009]. When used in combination, the sensitivity of urinary LAM 
ELISA with sputum smear microscopy was significantly higher than either 
test alone [74%, 95%CI: (65-82), 83/113 vs LAM ELISA: 58%, (95%CI: 49-67, 
65/112); p=0.01 or Smear microscopy: 52%, 95%CI: (43-61), 59/113, p=0.001]. 
The sensitivity of urinary LAM ELISA combined with MTB/RIF was 
significantly higher than MTB/RIF or LAM strip testing alone [68%, 95%CI: 
(60-77), 77/113 vs MTB/RIF : 48%, 95%CI: (39-57), 54/113; p=0.002 or LAM 
strip:48%, 95%CI: (39-57), 55/113; p=0.003]. Nevertheless, the combined 
urinary LAM ELISA and MTB/RIF was not significantly higher than LAM 
ELISA alone [68%, 95%CI: (60-77), 77/113; vs 58%, (95%CI: 49-67, 65/112); 






















Table 4.2. Diagnostic accuracy of sputum smear microscopy, urinary MTB/RIF, TB LAM ELISA, LAM 
strip test (grade-2 cut-point) and their clinically relevant combinations 
 
#Indicates p<0.05 for a comparison of the sensitivity between different tests (e.g. urine MTB/RIF vs. 
LAM strip test) or combinations thereof; specific p-value: #1p=0.002; #2p=0.003; #3p=0.001; #4p=0.01;; 
#5p=0.03; #6p=0.009 non-significant p-values not shown. 
 
4.4. Diagnostic accuracy of sputum smear microscopy and urine-based 
diagnostics stratified by CD4 cell count 
 
Urine-based MTB/RIF sensitivity in patients with CD4≤200 cells/ml was 
significantly higher [54%, 95%CI: (43-65), 42/78] compared to [31%, 95%CI: 
(17-50), 8/26] for CD4>200 cells/ml (p=0.05). Urinary LAM ELISA and strip 
tests also had higher sensitivities in patients with CD4<200 cells/ml (table 
4.3). All urine-based diagnostics had shown the highest sensitivities in 






All M. tuberculosis  
culture positive 
(N=113) 


































Urine LAM ELISA followed by 
urine MTB/RIF (performed if 







Urine LAM ELISA combined 



















different to patients with CD4<200 cells/ml. In contrast, the sensitivity of 
sputum smear microscopy was unaffected by decreasing CD4 cell count.  
 
Table 4.3. Sensitivities of sputum smear microscopy, urinary MTB/RIF, TB LAM ELISA, LAM strip 
test (grade-2 cut-point) and their clinically relevant combinations in any sputum/non-sputum M. 
tuberculosis culture positive patients stratified by CD4 cell count† 
 
 
#indicates p<0.05 for a comparison of the sensitivity between different tests or combinations thereof; 
specific p-value: #1p=0.02; #2p=0.05; #3p=0.02; #4p<0.001; #5p=0.002; #6p=0.03; #7p=0.001; #8p=0.02; 
#9p<0.001; #10p=0.004, #11p=0.002; #12p<0.001 
*p-values for comparisons between CD4 count >200 cells/ml and CD4 count ≤200 cells/ml 
@p-values for comparisons between CD4 count >200 cells/ml and CD4 count ≤100 cells/ml; 
@1p<0.001; @2p=0.003; @3p<0.001; @4p<0.01 
†9 culture positive patients with no available CD4 cell count results 
 
When urine-based diagnostics were used in combination or together with 
sputum smear microscopy, the highest overall sensitivity was in patients 
with a CD4<100 cells/ml using a combination of urine LAM ELISA and 
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diagnostic tests alone, test combinations performed similarly in different 
CD4 cell count strata to in the overall group (see Table 4.2 and 4.3).  
 
4.5. Diagnostic accuracy of sputum smear microscopy and urine-based 
diagnostics stratified by site of disease 
 
The sensitivities (95% CI) of smear microscopy, urinary MTB/RIF, LAM 
ELISA and strip test stratified by sites of M. tuberculosis culture positivity are 
shown in table 4.4. 
 
Table 4.4. Sensitivities of Sputum smear, GeneXpert, LAM ELISA, LAM strip test (grade-2 cut-point) 
and their clinically relevant combinations stratified with site of disease in M. tuberculosis culture 
confirmed TB/HIV coinfected patients.  
 
 
*There was a missing LAM ELISA result 
# P-values (p<0.05) of differences between combined diagnostic tests and individual tests, #1p=0.03; 


























































































Table 4.4 shows that all the tests perform better in patients that had both PTB 
and EPTB than the patients that were presented with PTB only or EPTB only; 
however there was lack of significant difference between each of these 
groups. Combined LAM ELISA and urine Xpert MTB/RIF had significantly 
better sensitivity than individual Urine Xpert MTB/RIF [65%, 95%CI: (53-75), 
44/68 vs 44%, 95%CI: (33-66), 30/68; p=0.02] in the PTB patients; more so the 
same diagnostic combination was significantly superior to individual LAM 
strip test (grade-2 cut-point) in patients with EPTB only [69%, 95%CI: (50-83), 
18/26 vs 39%, (95%CI: (22-57), 10/26; p=0.03]. In patients presenting with 
both PTB and EPTB, both combined diagnostic tests had similar sensitivities 
and were better than the individual test, notwithstanding lack of statistical 
significance between the combined tests and the individual tests. 
 
4.6. Diagnostic accuracy of urine-based diagnostics stratified by smear   
status 
 
Table 4.5 shows the sensitivity and specificity of urinary Xpert MTB/RIF, TB 
LAM ELISA, LAM strip test (grade-2 cut-point) and different combinations 
thereof in 59 sputum smear positive and 54 sputum smear-negative/sputum 
scarce patients. In SN/SS patients the sensitivities of urinary MTB/RIF, LAM 
ELISA and LAM strip test were 39%, 45%, and 3% respectively. A 
combination of urine MTB/RIF and ELISA had the highest overall sensitivity 
[60% (95% CI: 47-72)], which was better than urine MTB/RIF and LAM strip 
alone (60% vs 39%, p=0.03, and 37%, p=0.02 respectively), but not LAM 


















Table 4.5. The sensitivity of urinary Xpert MTB/RIF, TB LAM ELISA, LAM strip test (grade-2 cut-




#indicates p<0.05 for a comparison of the sensitivity between different tests (e.g. urine 
MTB/RIF vs. LAM ELISA) or combinations thereof within each group; specific p-value: 
#1p=0.04; #2p=0.03; #3p=0.02; #4p=0.02; #5p=0.05; p>0.05  
@ indicates p-values for comparison of sensitivity of SS/SN vs sputum positive; p<0.05 are 
highlighted in blue. 
*There was a patient who had no LAM ELISA result. 
 
These urine based tests had higher sensitivities in the SP patients than in the 















































































4.6.1. Diagnostic accuracy of urine-based diagnostics in sputum scarce (SS) 
and sputum smear-negative (SN) patients 
 
The sensitivity of urinary Xpert MTB/RIF, TB LAM ELISA and LAM strip 
test (grade-2 cut-point) in study patients stratified according to their ability 
to produce sputum and smear negativity is outlined in table 4.6. LAM ELISA 
had a superior sensitivity [60%, 95%CI: (39-78), 12/20] in patients who could 
not produce sputum compared to both urinary Xpert MTB/RIF and LAM 
strip test (grade-2 cut-point), notwithstanding there was no statistical 
significance. Also, urine LAM ELISA performance in the SS patients was 
higher than that of the SN group [60% (39-78), 12/20 vs. 36% (22-53), 12/33 
(p=0.1)]. There was generally a poor performance throughout all diagnostic 
tests within the sputum smear-negative patients. Xpert MTB/RIF had a 
sensitivity of 38%, (95%CI: 24-55, 13/34) which was equivalent to urine LAM 





























Table 4.6. Sensitivity of urinary Xpert MTB/RIF, TB LAM ELISA, LAM strip test (grade-2 cut-point) 
and combinations thereof, stratified by smear status and ability to produce a sputum sample (sputum 
scarce). 
 
# indicates p-values for a comparison of the sensitivity between different tests (e.g. urine MTB/RIF vs. 
LAM ELISA) or combinations thereof between each patient group (i.e. SS and SN).  
*denotes p<0.05 for a comparison of differences in sensitivity within each group for a specific test or 
combinations thereof; *1p=0.03 
There was an increase in the test performance when diagnostic tests were 
combined. Combined Xpert MTB/RIF and LAM strip test (grade-2 cut-point) 
had equivalent moderate sensitivities in both the SS and SN patients. There 
was, however, a significant difference, in the SN patients, between the 
combined Xpert MTB/RIF and LAM strip test (grade-2 cut-point) [59% 
95%CI: (42-74), 20/34 vs 32%, 95%CI: (19-49), 11/34 (p=0.03)-LAM strip test 
alone].  
 
4.7. The effect of urine centrifugation on urine MTB/RIF performance 
 
In 33% (38/116) of M. tuberculosis culture positive patients there was 











































































unprocessed urine and 2-10 mls of centrifuged and pelleted urine. The 
median (IQR) of urine used for pelleting was 10 (5-10) ml. The sensitivity of 
urine Xpert MTB/RIF was higher using 2-10ml centrifuged and pelleted vs. 
1ml unprocessed urine [42% (95%CI: 26-58; 16/38) vs. 8% (95%CI: 0-16; 
3/38), p<0.001]. There was no significant increase in sensitivity when 6-10mls 
of urine were centrifuged and pelleted compared with 2-5mls [48% (95%CI: 
29-67; 13/27) vs. 28% (95%CI: 0-54; 3/11), p=0.2].  
 
4.8. Conclusion and brief discussion (a further more detailed discussion is 
presented at the end of the thesis) 
 
The main findings of this study show that performing urine MTB/RIF was 
possible and offers potential utility for non-sputum based diagnostic, 
especially for sputum scarce and sputum smear-negative patients, the 
majority of whom had EPTB. In this patient group urine MTB/RIF detected 
close to half of all TB cases. Furthermore, concentrating 2-10mls of urine and 
using the urine pellet in the MTB/RIF improves sensitivity by approximately 
34%. Moreover, combining two or more urine-based diagnostic tests 
improves sensitivity. For instance, the combination of the urine LAM ELISA 
with urine MTB/RIF was able to detect approximately three quarters of all 
sputum scarce and smear-negative TB cases and was better than using urine 
MTB/RIF or the urine LAM strip test alone. In patients with CD4≤100 
cells/ml the combined urine MTB/RIF and urine LAM strip test detected 
87% of TB cases were sputum smear alone would detect 57%. Of the all 
sputum smear negative TB cases approximately half were correctly identified 
by the same combination. 
Over the past decade there has been an increased burden of smear-negative 
and sputum scarce TB in HIV co-infection and high mortality rate [6]. 
Moreover culture takes 4-6 weeks with low sensitivity in paucibacillary cases 
[43]; whilst sputum smear microscopy has suboptimal sensitivity with 50-













misdiagnosis and delayed diagnosis of TB leading to high rates of morbidity 
and mortality [45]. Nevertheless, the use of MTB/RIF on urine could provide 
both a rapid diagnosis and rifampicin susceptibility test result for new 
hospital admissions within 24 hours. The advantage of urine MTB/RIF over 
the other urine-based diagnostics is its ability to detect rifampicin resistance.  
However, there were some limitations to this study. There was no sputum 
MTB/RIF performed which could have been used to compare the 
performance of MTB/RIF using urine and sputum as samples. More so, the 
results of this study were not used for treatment decisions therefore it 
became difficult to comment on the impact of the study. In addition some of 
the urine samples were inadequate for centrifuging for the MTB/RIF assay.  
Lastly, all the urine-based diagnostic tests were performed on frozen samples 
and this could have had a negative effect on the test results. 
Combining the tests yielded an increased sensitivity than each test alone. 
There was a significantly remarkable increase in the sensitivity of combined 
tests within patients who were severely immunocompromised compared to 
patients with CD4>200 cells/ml. MTB/RIF still detected TB in the patient 
with PTB only; GUTB might be the highly suspected infection resulting in 
urine Xpert positivity in these patients due to its silent and often 
asymptomatic characteristics in its latent phase [44]. In the EPTB patients 
LAM ELISA test performed better than other tests offering even a higher 
sensitivity when used together with MTB/RIF. The introduction of these 
urine-based adjunctive tests in resource-constrained settings as a way of 
complementing the underperforming smear microscopy is imperative 
especially with urine MTB/RIF having the advantage of detecting rifampicin 
resistance. Centrifuging and pelleting urine has been demonstrated to 
improve performance in urine Xpert MTB/RIF and this conforms to previous 
studies that have centrifuged non-sputum samples like CSF and pleural fluid 













centrifuged and pelleted at higher gravitational force for more at least 20 























There are almost 9 million cases of TB and approximately 2 million TB-
related deaths annually . South Africa has the fifth highest global TB 
incidence and 60% of these new cases are HIV-coinfected [16]. The biggest 
weakness in the management of persons with TB and HIV co-infection is the 
problem of mis- and delayed diagnosis [17]. The inability of these patients to 
produce sputum samples, the often paucibacillary disease and consequent 
poor performance of sputum smear-microscopy, and high incidence of 
extrapulmonary TB (EPTB) underpin this diagnostic problem [13]. Thus, 
non-sputum-based rapid and effective diagnostic tools are urgently needed  
TB HIV co-infection [45]. Urine, being easy to collect and readily available is 
an ideal target biological sample [69]. The urine LAM strip test, being a 
simple, rapid bedside tool, is a potentially ideal tool for use in low-resource 
high burden primary care settings [53]. The Xpert MTB/RIF is an exciting 
novel sputum-based diagnostic that may have possible utility when applied 
to urine. This study investigated the utility of these novel urine diagnostic 
tools for TB diagnosis in a high HIV prevalent setting. This study sought to 
clarify whether the use of a LAM strip grade-2 cut-point instead of the 
manufacturer’s recommended cut-point improved inter-rater agreement and 
LAM strip rule-in performance in ambulatory patients presenting at a health-
care facility. Furthermore, the study also sought to investigate if, in patients 
co-infected with HIV and advanced immunosuppression, the combination of 
urinary LAM and Xpert MTB/RIF could improve diagnosis in this 
vulnerable patient group.  
 
This study shows that the use of the grade-2 cut-point and not the 
manufacturer’s suggested grade-1 cut-point for the urine LAM strip test 
improved the inter-reader agreement and test specificity in an ambulatory 













using the manufacturer’s suggested grade-1 cut-point are highly likely to be 
associated with false positive results due to NTMs and some fungal species 
such as Candida; making use of the grade-2 cut-off point helps in the 
elimination of most of these false positives. This however, resulted in the loss 
of true positive grade-1 results, which is a possible reason why the sensitivity 
dropped down significantly [5, 65, 67]. Specificity improved significantly, but 
only at the expense of sensitivity. These findings are similar to those of Peter 
et al. whose study investigated urine LAM strip performance in a 
hospitalised HIV-infected patient cohort with advanced immunosuppression 
also in Cape Town, South Africa [6], but differ from those of Lawn et al. in an 
ARV-screening clinic [19]. The reason for these difference remain unclear as 
the HIV-infected patients evaluated in this study and that of Lawn et al. were 
similar with respect to the levels of immunosuppression. One possible 
explanation is that the 24 LAM strip-positive test results in the Lawn et al. 
study had high corresponding LAM ELISA optical densities and were thus 
likely to have had strongly positive LAM strip tests (grade 2-5) [88], thereby 
avoiding the presence of the confusing faintly positive (grade-1) bands. 
Unfortunately though, given the very low sensitivity of the urine LAM strip 
test (24% in HIV-infected) in this out-patient cohort, even cut-point 
optimization to improve rule-in test utility could only marginally improve 
PPV. The low sensitivity of the urine LAM strip test in this patient cohort 
was consistent with a number of studies performed with the LAM ELISA-kit 
in similar patient populations [65, 73, 87, 89]. Thus, it seems unlikely that the 
urine LAM strip will offer significant clinical utility in ambulatory primary 
care clinic patients with suspected TB, even if they are HIV co-infected. 
 
Despite the limited performance of urine LAM in ambulatory patients which 
this study confirms using the LAM strip test, studies of urine LAM (both the 
ELISA and now recently the strip test) show moderate sensitivity (~50%) 
amongst severely-ill hospitalised TB HIV co-infected patients with advanced 
immunosuppression. Higher urine LAM concentrations have been found to 













HIV co-infected patients with advanced immunosuppression have high TB-
related mortality and often present with disseminated disease which is 
sputum scarce or sputum smear-negative [90]. They are a particularly 
vulnerable, diagnostically challenging patient sub-group in whom prompt 
diagnosis and the early initiation of TB treatment may save lives [90]. Novel 
non-sputum diagnostic approaches are urgently needed and consequently, 
we hypothesized that the use of urine-based Xpert MTB/RIF alone or in 
combination with urine LAM strip testing may offer important clinical utility 
in hospitalized patients with suspected TB HIV co-infection and sputum 
scarce or smear-negative disease [45]. 
 
This study found that: i) urine-based MTB/RIF offered equivalent sensitivity 
to urine LAM (ELISA or strip test) in TB HIV co-infected patients with 
sputum scarce or smear-negative disease with the additional advantage of 
rifampicin drug susceptibility testing; ii) a combination of urine LAM ELISA 
and MTB/RIF testing could detect close to three quarters of sputum scarce 
M. tuberculosis culture positive patients; and iii) the pelleting of 2-10ml of 
urine prior to MTB/RIF testing significantly improves sensitivity [45]. 
Sputum-based Xpert MTB/RIF is currently being implemented for frontline 
TB diagnosis in South Africa as a replacement for smear microscopy [32, 34, 
45, 82], however, few data on the Xpert MTB/RIF performance in urine and 
other non-sputum samples is available. This study indicates that urine 
MTB/RIF could be considered as an alternative diagnostic tool in HIV-
infected hospitalised patients with suspected TB who are unable to produce 
sputum or have EPTB. Used in combination with urinary LAM, a diagnosis 
could be provided for close to three quarters of diagnostically destitute 
patients within 24 hours of admission.  
 
Although urinary M. tuberculosis culture is of little use amongst ambulatory 
HIV un-infected patients, a few studies in HIV-infected patients with 
advanced immunosuppression have found the diagnostic yield of repeated 













urine-based smear-microscopy, even in HIV-infected patients is dismal. In 
this study we found the sensitivity of urine-based Xpert MTB/RIF to be 48%, 
and significantly improved by the centrifugation of up to 10mls of urine. This 
result is not unsurprising given the known comparative limits of detection 
between urine culture (~10000 organisms/ml), sputum culture (10-100 
organisms/ml), Xpert MTB/RIF (~131 organisms/ml) and smear-
microscopy (10000 organisms/ml) [34, 81, 88, 91, 92].   
Similar studies on the performance of urine LAM and Xpert MTB/RIF were 
also carried out by Wood et al (2012). The study showed that approximately 
50% of all urine LAM ELISA positive patients were also urine Xpert 
MTB/RIF positive [34, 93]. The studies further suggested that since Xpert 
MTB/RIF only detects whole M. tuberculosis bacilli, the Xpert MTB/RIF 
positive results together with LAM antigenuria indicates strong possibilities 
of genitourinary TB [34, 93]. This study confirms the possibility of LAM 
antigenuria resulting directly from genitourinary TB where the LAM antigen 
passes directly into the urine without crossing the renal glomerular basement 
membrane [45, 93] 
 
It has been shown that the TB LAM Ag tests offer particular POC rule-in 
utility in hospitalised HIV infected patients with advanced 
immunosuppression [6], and have been proposed as a rapid tool to guide the 
rapid initiation of anti-TB therapy. In this study we demonstrate the 
potential use of urine Xpert MTB/RIF as an alternative rapid rule-in test for 
these hospitalised patients with advanced HIV-infection. Furthermore, the 
improved rule-in utility of the combination of urine Xpert MTB/RIF and TB 
LAM Ag is demonstrated. By contrast, the performance characteristics of the 
TB LAM Ag in our ambulatory patient group demonstrate that the urine 

















5.2. Study limitations 
 
Notwithstanding the exciting findings from this study, there were some 
limitations that need to be noted. The first arm of the study, that analysed the 
inter-reader agreement and performance of the urine LAM strip using two 
different cut-points in the out-patient department (OPD) patients, used data 
that came from a single study site. Moreover there were fewer HIV positive 
patients (n=74) compared to HIV negative patients (n=200). Intra-reader 
agreement was not done and evaluated. On the other hand, the second arm 
of the study had a shortfall of inadequate sample volumes. Hence many 
other procedures, such as pelleting urine samples that could have given 
better diagnostic performance were not carried out. Only 38/59 Xpert 
MTB/RIF negative samples were centrifuged and resuspended for the urine 
Xpert MTB/RIF, of which the volume used for the pelleting of samples 
ranged between 2-6ml due to the inadequate volumes. Some urine samples 
were missing. Only the sensitivity of the test was used as the diagnostic 
performance parameter. Urine Xpert MTB/RIF’s specificity would have been 
useful in the decision on whether to use the test as a ‘rule in’ or not. 
Furthermore, there was no sputum Xpert MTB/RIF done and this could have 




There is a need of carrying out further studies to clarify and substantiate the 
findings of this study. A larger study cohort will be more representative of 
the situation on the ground rather than a smaller sample size that was used. 
The first arm of the study was done in a single community; it is therefore 
recommended that more study sites be established in different parts of the 
Sub-Saharan Africa in order to get a clearer picture of the real situation. 
There is a great need of optimisation of the urine Xpert MTB/RIF before 
carrying out any investigation of study patients. This could involve the use 













different concentrations or colony forming units (CFUs) of M. tuberculosis. 
The spiked urine samples could be used to find out the limit of detection 
(LOD) of urine Xpert MTB/RIF. The same samples could be used to optimise 
the correct urine volume and speed or gravity of centrifugation. There is also 
need of using fresh urine samples rather than urine samples that have been 
archived in the fridge for long periods of time. Large volumes of urine 
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